Chul Kim

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study

Giuseppe Giaccone, Chul Kim, Jillian Thompson et al. · The Lancet Oncology · 2018 · 387 citations · Full text

Medicine, Immunology, Pathology +5

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

Nitin Roper, Anna‐Leigh Brown, Jun S. Wei et al. · Cell Reports Medicine · 2020 · 167 citations · Full text

Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs

Chul Kim, Vinay Prasad · Mayo Clinic Proceedings · 2016 · 122 citations

Medicine, Cancer Management, Clinical Endpoint +10

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

Neil J. Shah, Ghassan Al‐Shbool, Matthew Blackburn et al. · Journal for ImmunoTherapy of Cancer · 2019 · 118 citations · Full text

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

Chul Kim, Jae‐Lyun Lee, Min‐Hee Ryu et al. · Investigational New Drugs · 2009 · 82 citations

Gastrointestinal Oncology, Medicine, Cancer Management +6